Skip to main content

Table 1 Baseline and treatment characteristics of the Asian and non-Asian subsets (full analysis set)

From: Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1

Characteristic

Asian

Non-Asian

EVE + TRAS + PAC

PBO + TRAS + PAC

EVE + TRAS + PAC

PBO + TRAS + PAC

n = 198

n = 105

n = 282

n = 134

Median age, years (range)

53.0 (23–75)

51.0 (29–82)

55.0 (26–86)

52.0 (19–77)

Race, n (%)

 Asian

198 (100%)

105 (100%)

0

0

 Black

0

0

26 (9.2)

12 (9.0)

 White

0

0

214 (75.9)

97 (72.4)

 Native American

0

0

3 (1.1)

0

 Other non-Asian

0

0

39 (13.8)

25 (18.7)

Ethnicity, n (%)

 Chinese

145 (73.2)

75 (71.4)

0

0

 Indiana

1 (0.5%)

0

0

0

 Japanese

27 (13.6)

15 (14.3)

0

0

 Other Asian

25 (12.6)

15 (14.3)

0

0

 Hispanic/Latino

0

0

78 (27.7)

34 (25.4)

 Other non-Asian

0

0

204 (72.3)

100 (74.6)

Current disease status, n (%)

 Locally advanced

10 (5.1)

7 (6.7)

24 (8.5)

9 (6.7)

 Metastatic

188 (94.9)

98 (93.3)

258 (91.5)

125 (93.3)

Site of metastasis, n (%)

 Visceral

139 (70.2)

65 (61.9)

199 (70.6)

104 (77.6)

 Lung

91 (46.0)

43 (41.0)

126 (44.7)

60 (44.8)

 Liver

66 (33.3)

36 (34.3)

111 (39.4)

74 (55.2)

 Lung and liver

27 (13.6)

17 (16.2)

45 (16.0)

34 (25.4)

 Bone

85 (42.9)

54 (51.4)

125 (44.3)

63 (47.0)

 Bone only

9 (4.5)

5 (4.8)

11 (3.9)

2 (1.5)

 Others

142 (71.7)

77 (73.3)

196 (69.5)

99 (73.9)

ECOG PS, n (%)

 0

121 (61.1)

64 (61.0)

157 (55.7)

84 (62.7)

 1

77 (38.9)

41 (39.0)

125 (44.3)

50 (37.3)

ER and PgR status, n (%)

 ER and PgR negative (HR–)

85 (42.9)

47 (44.8)

123 (43.6)

56 (41.8)

 ER and PgR negative (HR+)

112 (56.6)

57 (54.3)

159 (56.4)

78 (58.2)

 Not assessable

0

1 (1.0)

0

0

 Missing

1 (0.5)

0

0

0

  1. aIndian subcontinent. ECOG PS Eastern Cooperative Oncology Group performance status, ER estrogen receptor, EVE everolimus, HR hormone receptor, PAC paclitaxel, PBO placebo, PgR progesterone receptor, TRAS trastuzumab